Meeting
2020 ASCO Virtual Scientific Program
Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results.
Authors
Youlia M. Kirova
Institut Curie, Paris, France
Youlia M. Kirova , Delphine Loirat , Frederique Berger , Manuel Rodrigues , Louis Bazire , Jean-Yves Pierga , Francesco Ricci , Kim Cao , Anne Vincent -Salomon , Fatima Laki , Cyrine Ezzili , Laurence Raizonville , Veronique Mosseri , Souhir Neffati , Mounia Ezzalfani , Alain Fourquet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT03109080
Citation
J Clin Oncol 38: 2020 (suppl; abstr 571)
DOI
10.1200/JCO.2020.38.15_suppl.571
Abstract #
571
Poster Bd #
63
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial.
First Author: Pierre Loap
Poster
2023 ASCO Annual Meeting
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.
First Author: Dinu Stefan
Poster
2023 ASCO Annual Meeting
Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.
First Author: Helen Mackay
Poster
2020 ASCO Virtual Scientific Program
Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
First Author: Navid Hafez